by Peter Ciszewski | Aug 2, 2018
Richard West, Founder and CEO of Baebies, discusses the public health program of newborn screening. Screening programs are often run by state or national governing bodies with the goal of screening all infants born in the jurisdiction. The number of diseases...
by Peter Ciszewski | Aug 1, 2018
Mr. Robert (Bob) E. Ward, Chairman of the Board and Chief Executive Officer of Eloxx Pharmaceuticals discusses the role of advocacy groups in drug development, especially for rare diseases such as cystic fibrosis (CF). Cystic fibrosis is a genetic disorder that...
by Peter Ciszewski | Jul 31, 2018
The Food and Drug Administration (FDA) approved Azedra (iobenguane I 131) injection for intravenous use for the treatment of adults and adolescents age 12 and older with rare tumors of the adrenal gland (pheochromocytoma or paraganglioma) that cannot be surgically...
by Peter Ciszewski | Jul 30, 2018
Mr. Robert (Bob) E. Ward, Chairman of the Board and Chief Executive Officer of Eloxx Pharmaceuticals discusses Right To Try, which is aimed at allowing terminally ill Americans to try medicines that have passed Phase 1 of the FDA approval process and remain in...
by Peter Ciszewski | Jul 29, 2018
Scientists at Cincinnati Children’s Hospital Medical Center have uncovered three distinct subtypes of eosinophilic esophagitis (EoE), an emerging food allergic disease which may provide a framework for developing precision medicines to treat this...
